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Breast cancer is a heterogeneous disease, divisible into a variable number of clinical subtypes. A fundamental question is 
how many etiological classes underlie the clinical spectrum of breast cancer? An etiological subtype reflects a grouping 
with a common set of causes, whereas a clinical subtype represents a grouping with similar prognosis and/or prediction. 
Herein, we review the evidence for breast cancer etiological heterogeneity. We then evaluate the etiological evidence with 
mRNA profiling data. A bimodal age distribution at diagnosis with peak frequencies near ages 50 and 70 years is a funda-
mental characteristic of breast cancer for important tumor features, clinical characteristics, risk factor profiles, and molecular 
subtypes. The bimodal peak frequencies at diagnosis divide breast cancer overall into a “mixture” of two main components 
in varying proportions in different cancer populations. The first breast cancer tends to arise early in life with modal age-at-
diagnosis near 50 years and generally behaves aggressively. The second breast cancer occurs later in life with modal age near 
70 years and usually portends a more indolent clinical course. These epidemiological and molecular data are consistent with 
a two-component mixture model and compatible with a hierarchal view of breast cancers arising from two main cell types of 
origin. Notwithstanding the potential added value of more detailed categorizations for personalized breast cancer treatment, 
we suggest that the development of better criteria to identify the two proposed etiologic classes would advance breast cancer 
research and prevention.
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Clinically, breast cancer is widely recognized as a heterogeneous 
disease. In this commentary, we focus instead upon the etiological 
perspective of breast cancer heterogeneity. By etiological hetero-
geneity, we mean breast cancer subtypes (components, classes, or 
groupings) that share common sets of causes. This is distinct from 
a clinical subtype, which refers to tumors with common prognos-
tic characteristics and/or predictive features (response to targeted-
treatment) (1).
As efforts proceed to improve the taxonomy of clinical breast 
cancer, a fundamental question persists; how many etiological sub-
types actually exist? Clinical taxonomic systems have defined mul-
tiple classes in an effort to optimize therapeutic management. At its 
extreme, this approach translates into “precision” or “personalized” 
medicine, with a view that each person’s tumor is unique.
We propose a more parsimonious view for breast cancer etiol-
ogy, which we believe is consistent with a hierarchal view of breast 
cancer derived from two main cell types of origin (2–9). We show 
that any given breast cancer molecular or clinical category dem-
onstrates a mixture of two stereotypical age-specific incidence 
patterns with bimodal peak frequencies near ages 50  years and 
70 years. We hypothesize that the consistency of this pattern sup-
ports a two-component mixture model, where different molecular 
and/or clinical categorizations represent variable combinations of 
two etiological subtypes. In this model, it is the difference in the 
relative distributions of the two putative subtypes that endows any 
given breast cancer categorization with its distinguishable biologi-
cal features.
Historical Developments in the 
Understanding of Breast Carcinogenesis 
and Pathogenesis From an epidemiological 
Perspective
Multistage (Log-Linear) Cancer model
More than 50 years ago, Armitage and Doll noted that cancer rates 
rise exponentially with advancing age for a number of epithelial 
malignances (10–12), thus providing the theoretical foundation 
for multistage tumor initiation, promotion, and progression (13–
15). An epidemiological prediction of the multistage cancer model 
is a log-linear (or log-additive) relationship between cancer inci-
dence and chronological age with a linear (or steady) rise in the 
logarithm of cancer rates as a function of the logarithm of age at 
diagnosis.
However, breast cancer incidence does not demonstrate an 
exponential increase with advancing age. Incidence rates slow 
before age 50  years (Figure  1A). The change point in incidence 
has been termed “Clemmesen’s hook” after its discoverer, Johannes 
Clemmesen (16,17). Clemmesen’s hook is characteristic of female 
breast cancers worldwide (18–20), coincides with the female cli-
macteric, and is not found among male breast cancers (21).
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To account for the distinctive incidence rate pattern for breast 
cancer, Pike et al. introduced the concept of “breast tissue age” as a 
better marker of risk than chronological age (22). In his model, key 
reproductive events affect the shape of the age-specific incidence 
rate curve. Specifically, risk factors accelerate and protective factors 
attenuate breast tissue aging, with Clemmesen’s hook representing 
the net effect. Others have refined the Pike model (23–26); how-
ever, a key feature of all of these models is that all breast cancers 
share a common pathogenesis, reflected in a single, age-specific 
incidence rate curve.
Two-Component Cancer Model
Lilienfeld (27) and de Waard (28–30) pioneered the concept that 
breast cancers develop by two distinct pathways (rather than 
one), each with a different age-specific incidence rate curve. The 
first pathway results in mainly premenopausal tumors with peak 
occurrence early in life, similar to estrogen receptor (ER)–nega-
tive cancers in the general US population (Figure 1A). The sec-
ond pathway results in predominantly postmenopausal cancers 
with peak incidence later in life, similar to late-onset ER-positive 
cancers (Figure 1A). In this model, Clemmesen’s hook can be seen 
as the confluence or superimposition of the age-specific incidence 




The menopause transition was predicted to affect incidence rates 
of ER-positive more than ER-negative breast cancers, given the 
presumed greater role of sex-steroid hormones in the pathogenesis 
of hormone sensitive cancers (33,34). Nonetheless, and somewhat 
paradoxically, menopause [or rather its surrogate, age 50  years 
(35,36)] is associated with greater impact upon ER-negative than 
ER-positive cancers (31,33,34) (Figure 1A). ER-negative rates rise 
rapidly early in life then flatten or fall soon after menopause (37), 
whereas ER-positive rates rise continuously irrespective of meno-
pause, albeit more slowly after age 50 years.
The different incidence rate patterns by ER expression rep-
resent an age interaction or effect modification. Under the null 
hypothesis of no interaction, the age-specific incidence rates for 
ER-positive and ER-negative cancers would be parallel on the log 
scale (38–40), yielding a constant incidence rate ratio (IRR) irre-
spective of age at diagnosis (IRRERneg to ERpos = constant for all ages). 
We also make a distinction between quantitative (noncrossover) 
and qualitative (crossover or reversing) age interactions (37–40). 
A quantitative age interaction varies in magnitude but not direc-
tion, whereas a qualitative interaction differs in both magnitude 
and direction. At the extreme ages in Figure 1A, the incidence rate 
ratio of ER-negative to ER-positive cancer is 2.3 during ages 20 
to 24 years (IRRERneg to ERpos > 1.0) and the incidence rate ratio of 
ER-negative to ER-positive cancer is 0.10 during the ages 80 to 
84 years (IRRERneg to ERpos < 1.0). True qualitative or reversing inter-
actions are considered rare (40–42) but, when found, can be statisti-
cal surrogates for age-dependent etiological heterogeneity. In the 
context of a qualitative age interaction, Clemmesen’s hook can be 
further seen as the crossover in falling ER-negative rates and rising 
ER-positive rates.
Bimodal Age Distributions at Diagnosis
If breast cancer followed the log-linear incidence curve described by 
Armitage and Doll (10–12), breast cancer cases in the general pop-
ulation would be predicted to show a unimodal age distribution at 
diagnosis. In contrast, breast cancer overall demonstrates a bimodal 
pattern, with the modal ages near 50 and 70 years representing the 
central tendencies for the early-onset and late-onset breast cancers 
(Figure 2A). Density plots are constructed with 1-year increments 
using a “smoothing” method for the corresponding age distribu-
tions at diagnosis (31,43), where the area under the curve includes 
all of the breast cancer cases in a given population.
Crossing ER-positive and ER-negative age-specific rates 
(Figure  1A) also shows bimodal age distributions at diagnosis 
Figure 1. Breast cancer case and population data were obtained from 
the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results 9 Registries Database from 1990 through 2010 among women 
with invasive estrogen receptor (ER)–positive and ER-negative breast 
cancer. The dataset included thirteen 5-year age groups (ages 20–24, 
25–29, …, 80–84 years) and four 5-year time periods (1991–1995 1996–
2000, 2001–2005, 2006–2010), spanning 16 partially overlapping 10-year 
birth cohorts, referred to by mid-year of birth (1911, 1916, …, 1986). We 
used the age–period–cohort framework to obtain the fitted or longitu-
dinal age-specific incidence rate curve for the mid-cohort, adjusted for 
period effects (A) and the fitted temporal trends (B). A) Age-specific inci-
dence rates for ER-negative cancers rise rapidly early in reproductive 
life and then flatten or fall. Rates for ER positive cancers rise rapidly 
early in life and then continue to rise at a slower pace. B) ER-positive 
and ER-negative temporal trends have diverged over time. ER-positive 
rates have risen, whereas ER-negative rates have fallen.
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(Figure 2B) (31,43), as do many other important breast cancer 
features such as tumor size, lymph nodal status, and histological 
grade (44,45). Although the modal ages of 50 and 70 years have 
been robust irrespective of breast cancer characteristic, the rela-
tive distributions (or mixtures) for the early-onset and late-onset 
breast cancer subtypes can vary by specific stratifying factor, pro-
viding that class with distinguishable features. In general, high-risk 
tumors such as ER-negative cancers have bimodal breast cancer 
patterns with a predominant early-onset peak (Figure 2B). Lower-
risk tumors, such as ER-positive cancers, have bimodal breast can-
cer patterns with a more dominant late-onset peak (Figure 2B).
Age-Adjusted Secular Trends
Recent studies in the United States show an unexpected diver-
gence of ER-positive and ER-negative breast cancer trends 
(46–48); ER-positive cancers have risen over the long term, 
whereas ER-negative breast cancers have declined (Figure 1B). 
Theoretically, divergent ER trends in the United States could 
have resulted from statistical anomalies (49), changes in assay 
methodology or application of lower thresholds for classify-
ing ER tests as positive (50), and/or the implementation of 
organized screening mammography (51,52). However, secular 
trends in other countries with better control of these poten-
tially confounding factors (eg, Denmark) showed similar trends 
as in the United States (53), consistent with the hypothesis that 
divergent ER-positive and ER-negative trends might be due 
to changes in different risk factor profiles by ER subtype over 
time (47,48,54).
Biostatistical models
Our group has leveraged the application of biostatistical models to 
complement descriptive epidemiology. First, we used two-compo-
nent mixture models to determine whether bimodal age distribu-
tions at diagnosis fitted the data better than a single density (55) 
(Figure 2, A and B). Then, to confirm qualitative age interactions (eg, 
Figure  1A), we used age–period–cohort (APC) models to evaluate 
age-specific effects independent of calendar-period effects (that relate 
to screening, changing diagnostic and/or practice patterns) and/or 
birth-cohort effects (generational and/or exposure factors) (56,57).
Two-Component Mixture Models
We initially identified three distinct age-specific incidence rate 
patterns that were closely associated with seven histopathologi-
cal breast cancer subtypes (58). Incidence rates of infiltrating duct, 
tubular, and lobular carcinomas rose rapidly until age 50  years, 
then increased more slowly, similar to rates for breast cancer 
overall. Rates for medullary and inflammatory breast carcinomas 
increased rapidly until age 50 years, then flattened or fell, similar to 
ER-negative rates (Figure 1A). Finally, rates for papillary and muci-
nous carcinomas increased steadily with age, similar to ER-positive 
rates (Figure 1A) and much like cancers at many other organ sites 
such as colorectal cancer (12).
Notwithstanding the three distinct incidence rate patterns, 
two-component mixture models demonstrated that six of the his-
topathological subtypes had bimodal age distributions at diagno-
sis with early-onset and/or late-onset peak frequencies around the 
Figure 2. Invasive female breast cancer case data were obtained from the 
National Cancer Institute’s Surveillance, Epidemiology, and End Results 
9 Registries Database from 1990 through 2010 database overall and for 
estrogen receptor (ER)–positive and ER-negative cancers. Bimodal breast 
cancer populations have fluctuated over time likely because of complex 
interactions between age-related biologic, risk factor, and screening 
phenomena, as previously described (186). For illustration, this figure 
has been restricted to the 1995 to 1998 period, during which a bimodal 
female breast cancer population was evenly distributed between early-
onset and late-onset subtypes. Age distributions at diagnosis (or density 
plots) with 95% confidence intervals were constructed in 1-year age incre-
ments using a kernel density estimator applied to the corresponding age-
at-diagnosis frequency histogram. The area under the curve represents 
100% of the cancer records. The vertical axis shows the smoothed distri-
bution (or proportion) with the frequency value × 100 = percentage distri-
bution. A) Density plot for breast cancer overall demonstrates a bimodal 
age distribution at diagnosis with the modal ages near 50 and 70 years 
representing the central tendencies for early-onset and late-onset breast 
cancers. B) Density plot for ER-negative tumors also shows a bimodal 
age distribution at diagnosis with a dominant early-onset mode near 
age 50 years and a minor mode around age 70 years. Density plot for 
ER-positive tumors shows bimodal age distributions at diagnosis with a 
dominant late-onset mode near age 70 years and a minor mode around 
age 50 years. C) The risk for breast cancer–specific death can be expressed 
as an annual hazard rate, which describes the instantaneous rate of dying 
from breast cancer in a specified time interval (ie, percentage dying per 
year) after diagnosis among women who are alive at the beginning 
of that time interval. Nonparametric hazard function estimators were 
applied that modeled the hazard profile of ER-positive and ER-negative 
cancers, allowing both the shape and magnitude to be estimated free of 
ad hoc mathematical assumptions. Specifically, the hazard rate curves 
were generated using cubic splines with joinpoints selected by Akaike’s 
information criteria and 95% confidence intervals applied with bootstrap 
resampling (187–189). Bimodal age distributions at diagnosis among 
women (B) are associated with two very different cancer-specific out-
comes. ER-negative hazards for breast cancer death peak near 7.5% per 
year approximately 2 years after initial diagnosis and then decline rapidly. 
ER-positive hazards lack a sharp peak but are relatively constant at 1% to 
2% per year. Falling ER-negative and constant ER-positive hazards cross 
over approximately 8 years after breast cancer diagnosis.
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stereotypical ages of 50 and 70 years (45). The one notable excep-
tion was medullary carcinoma, which showed a unimodal age dis-
tribution with mode close to age 50 years. Medullary carcinomas 
are linked to the loss of BRCA1 function (59–61), which we propose 
may represent the closest known approximation to an etiologically 
pure early-onset subtype of breast cancer.
Similar to ER-positive and ER-negative breast cancers 
(Figure 2B), the bimodal peaks for different histopathological cat-
egories do not sharply divide cancers into pure groups, but rather 
reflect central tendencies of what we propose are two fundamental 
etiological classes. Breast cancers that develop at extreme ages are 
likely to be highly enriched for one etiological class, but both of 
these classes span the entire lifespan, with substantial mixing dur-
ing the middle years, when many cancers occur. The mixing frac-
tion or proportion of each etiological group varies within a class of 
breast cancers depending on its definition; however, the peak ages 
remain near ages 50 and 70 years.
APC Models
A useful APC function is the fitted (or longitudinal) age-specific 
incidence rate curve (37,62) (Figure 1A). The fitted curve stitches 
together the age-specific incidence rates from a collection of birth 
cohorts, each one observed over a limited and variable age span (ie, 
younger cohorts are observed at younger ages and older cohorts at 
older ages). The resulting curve estimates the age-specific rates of 
the middle or reference cohort over the entire age range. In con-
trast with the typical cross-sectional, age-specific incidence rate 
curve that may be confounded by period and cohort effects (63,64), 
the fitted curve is conditioned upon cohort and adjusted for period 
changes.
Clemmesen’s menopausal hook for breast cancer overall was 
once dismissed as a birth-cohort artifact (65), where the progres-
sive increase in breast cancer risk from one generation to the next 
gave the appearance of falling incidence rates among older per-
sons (64). This view is refuted by APC models (37), which dem-
onstrate that the Clemmesen’s phenomenon is a true age-related 
event that persists in the fitted age-specific incidence rate curve 
(Figure 1A). Similar modeling approaches confirm that the qualita-
tive age interaction remains for the fitted curves for ER-positive 
and ER-negative breast cancers, respectively (37).
analytic epidemiology
Consistent with descriptive epidemiology and biostatistical mod-
els, analytic epidemiology also supports a two-component breast 
cancer mixture model based upon the identification of major risk 
factors and genetic susceptibility.
Risk Factor Epidemiology
Despite the well-established protective effect of full-term preg-
nancy for breast cancer overall (22,66,67), it has been suggested, 
albeit without total agreement (68,69), that parity is associated with 
an early increase in risk, followed by long-term protection (70–86). 
Alternatively, the early risk and late protection for parity could reflect 
another qualitative (crossover or reversing) age interaction for breast 
cancer (40), where parity increases risk of early-onset subtypes and 
reduces risk of late-onset ones (37). Indeed, parity and multiple live 
births are associated with reduced risk for ER-positive and luminal 
A  intrinsic breast cancer subtypes (Table 1) and increased risk of 
ER-negative tumors (specifically, ER-negative basal-like or triple-
negative intrinsic breast cancer subtypes) (87–91). The combined 
effect of early age at first birth and lack of breast feeding appears 
to impart an especially high risk for basal-like (triple-negative and 
BRCA1) cancers (88,89,92–98), particularly among some specific 
ethnic groups.
Obesity is another risk factor with dual effects by age at diag-
nosis and ER status (90,99,100), which are possibly mediated 
through the cholesterol metabolite 27-hydroxycholesterol (101–
103). Body weight has a direct association with postmenopausal 
breast cancer and an inverse relationship with premenopausal 
cancer (104–109). Obesity also has a stronger positive association 
with hormone receptor–positive than hormone receptor–nega-
tive cancers (101,102,110), although obesity may also increase 
the risk of basal-like, triple-negative, and inflammatory breast 
cancers (88,90,111,112). Rising ER–positive cancers among older 
women and falling ER–negative tumors among younger women 
(Figure 1B) are consistent with rising obesity and declining par-
ity in the United States (113) and Denmark (114), as well as many 
other parts of the world (115). Other studies have also found dual 
risk factor associations by ER status [reviewed in (54)].
Genetic Susceptibility
Many genetic loci are known to contribute to the risk of familial breast 
cancer, including highly penetrant deleterious germline mutations in 
the BRCA1 and BRCA2 tumor suppressor genes. Of note, BRCA1 and 
BRCA2 breast cancers are distinct in their expression of hormone 
receptors (116–118). Roughly 75% of BRCA1 breast cancers are ER 
negative and 25% are ER positive. On the other hand, 75% of BRCA2 
breast cancers are ER positive and 25% are ER negative, similar to 
breast cancer in the general population. Recent genome-wide associ-
ation studies also have identified more than 75 low-penetrant suscep-
tibility loci with evidence for specificity by tumor subtype (119–129). 
For 13 loci (119), there is greater relative risk for ER-positive than 
ER-negative cancers. For two notable exceptions (single nucleotide 
polymorphisms rs6828523 and rs7072776), the relative risk is oppo-
site for ER-positive and ER-negative tumors (119), consistent with 
risk factor differences by ER expression. Lastly, there are a number of 
susceptibility loci only for ER-negative but not ER-positive tumors 
(eg, the hTERT loci) (130, 131).
molecular Class Discovery and Prognosis
Analyses of gene-expression profiling data reveal that ER-positive 
and ER-negative tumors are fundamentally distinct diseases in 
molecular terms (132). There are two predominantly ER-positive 
intrinsic molecular subtypes (ie, luminal A and luminal B) and two 
predominantly ER-negative intrinsic subtypes (ie, HER2-enriched 
and basal-like) (Table  1). The intrinsic molecular subtypes are 
largely distinguished by the expression of genes involved in luminal 
epithelial differentiation (eg, ER and PR genes), proliferation (eg, 
Ki67 gene), human epidermal growth factor receptor 2 pathway 
(eg, HER2 gene), and basal differentiation (133–136).
The intrinsic molecular signatures are robust across multiple 
genomic platforms (137,138), apply to both carcinoma in situ and 
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invasive breast cancers (139–141), and are identifiable within dif-
ferent racial groups (142–144). Although the intrinsic gene set was 
originally developed through agnostic profiling, the power of this 
approach reflects its ability to define molecular subtypes that vary 
with respect to prognosis and treatment (134,136,137,145–156). 
The intrinsic subtypes have been variously approximated with 
immunohistochemical staining algorithms (Table  1); however, 
there can be considerable discordance between the gene-based and 
immunohistochemical-based expression profiles for the intrinsic 
subtypes (157–159).
Luminal breast cancers are the most heterogeneous intrinsic 
subtypes, with the luminal A  tumors distinguished by the high 
expression of luminal epithelial genes, low expression of the Ki67, 
and the best prognosis (160,161). The difference between the lumi-
nal A and luminal B gene patterns is less distinct than the differ-
ence between the luminal A and basal-like subtypes, which appear 
to be anticorrelated (88,146,162–165). Among the intrinsic sub-
types, the basal-like tumors have the most unique and distinctive 
genomic profile (132,166–169); they are in many ways more simi-
lar to squamous cell carcinomas of the lung and high-grade serous 
ovarian carcinomas than to all other subtypes of breast cancer 
(9,170). Basal-like tumors are enriched with BRCA1-mutated and 
triple-negative breast cancers but also include some special histo-
pathological subtypes such as medullary and adenoid cystic tumors 
(138,157,158,171). Finally, the HER2-enriched (HER2E) subtype 
shows a global gene signature that lies more closely to the luminal 
than basal-like cancers (172), with HER2 cell surface expression 
possibly playing an important role in regulating the luminal cancer 
stem cell population (5–7).
If every molecular subtype was a unique biological entity, one 
might anticipate that each would demonstrate a distinct age-spe-
cific incidence rate curve and unimodal age frequency distribu-
tion at diagnosis (45,58). Unfortunately, incidence rate data are 
not readily available for the intrinsic molecular signatures because 
gene-expression analyses have mostly been limited to case series 
and/or small observational studies from convenience and/or 
hospital-based samples. Nonetheless, in an early study that used 
the National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER) Residual Tissue Repository (164,173), we 
estimated the age-specific incidence rates for the molecular sub-
types with immunohistochemical staining of breast cancer tissue 
microarrays and imputed population data. Luminal A (defined as 
ER positive and HER2 negative) incidence rates rose continuously, 
although more slowly after age 50  years (similar to ER-positive 
cancers) (Figure 1A). Basal-like rates (defined as ER negative and 
HER2 negative) increased rapidly early in life then flattened or 
fell (similar to ER negative cancer) (Figure  1A). These patterns 
are consistent with subsequent studies from the California Cancer 
Registry (174–177) and emerging data from SEER’s large-scale 
population-based database (178).
Given the limited availability of population-based incidence 
rate data, we applied the intrinsic gene set classification algo-
rithm (147) to approximately 2000 breast cancer cases reported by 
METABRIC Group (179,180). Although METABRIC described 
10 distinct groups based primarily upon copy number data, the age 
distribution patterns by gene expression–defined intrinsic molecu-
lar subtypes are reminiscent of the bimodal patterns defined by ER 
protein expression (Figure 2B). Luminal A and luminal B cases had 
bimodal age distributions with predominant late modes near age 
70  years and minor modes near age 50  years (Figure  3A), simi-
lar to ER-positive cancers in SEER (Figure 2B). Basal-like cancers 
had an early-onset mode around age 50 years (Figure 3, A and B), 
similar to ER-negative cancers in SEER (Figure 2B). The HER2-
enriched age distribution lay midway between the luminal and 
basal-like cancers (Figure  3A). Combining the HER2-enriched, 
luminal A, and luminal B cases into a single non-basal-like group 
did not appreciably alter the bimodal shape of the molecular sub-
types (Figure 3B).
In METABRIC, hazard rates for breast cancer–specific death 
for basal-like, HER2-enriched, and luminal B tumors peaked near 
7.5% per year approximately 2 years after initial breast cancer diag-
nosis then declined (Figure  3C), similar to ER-negative cases in 
SEER (Figure  2C). Luminal A  hazard rates lacked a sharp peak 
and were relatively constant at 2% to 2.5% per year (Figure 3C), 
similar to ER-positive cases in SEER (Figure 2C). Overlaying the 
hazard rate curves for non-basal-like and basal-like cancers demon-
strated crossing hazard rates approximately 8 years after diagnosis 
(Figure  3D), similar to ER-positive and ER-negative cancers in 
SEER (Figure 2C).
Directions for Future research
We present the hypothesis that breast cancer comprises two fun-
damental etiological components, classes or subtypes; which, as 
of yet, are not specifically defined but which induce bimodal age 
distributions at diagnosis irrespective of the classification applied. 
The two putative main etiological subtypes are characterized by 
sharply contrasting tendencies related to age-specific incidence 
Table 1. Immunohistochemical staining for the intrinsic breast cancer molecular subtypes*
IHC subtype (%)† ER and/or PR HER2 Ki67 Intrinsic subtype
Luminal A (73%) Positive Negative Low Luminal A
Luminal B (10%) Positive Negative or positive Low or high Luminal B
HER2 positive, nonluminal (5%) Negative Positive Not needed HER2-enriched
Triple-negative (12%) Negative Negative Not needed Basal-like
* There are two predominantly hormone-positive (estrogen receptor [ER] and/or progesterone receptor [PR]) intrinsic molecular subtypes (luminal A and luminal  
B) and two predominantly hormone-negative intrinsic subtypes (human epidermal growth factor receptor 2 [HER2] enriched and basal-like) (133–136). Additionally, 
there are two predominantly HER2-positive intrinsic molecular subtypes (luminal B and HER2 enriched) and two predominantly HER2-negative intrinsic subtypes 
(luminal A and Basal-like). Adapted from Goldhirsch et al. (157). IHC = immunohistochemical.
† Estimated percentage distribution for IHC-derived subtypes among women with breast cancer and known ER, PR, and HER2 expression in the general population 
of the United States in 2010, provided by the National Cancer Institute’s SEER database (178).
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rates, clinical prognosis, risk factor profiles, and somatic gene and 
protein expression. ER expression by age at diagnosis provides an 
epidemiologically useful correlate for our two-component breast 
cancer mixture model, but it is not a perfect surrogate.
From the molecular perspective, multianalyte genomic profil-
ing has revealed many novel breast cancer subtypes with distin-
guishable, if not distinctive, clinical tendencies. We speculate that 
these categorizations also may reflect varying mixtures of two main 
etiological components, as demonstrated by a ubiquitous bimodal 
age distribution at diagnosis. Presently, the luminal A and basal-like 
molecular signatures are the most clearly distinguishable subtypes 
(Figure 3A) and appear to be polar opposites at most every level 
(3,6,163,181).
Furthermore, emerging molecular evidence shows that across 
different types of cancer, breast cancer is one of the few cancers 
with two major divisions. One division consists of basal-like tumors 
and the other is composed of luminal A, luminal B, and HER2-
enriched cancers (9,170), which we have conceptualized with a car-
toon in Figure  4. These data, together with the epidemiological 
findings reported herein, suggest that breast cancer overall may be 
viewed as a hierarchal disease derived from two main cell types of 
origin (ie, basal/myoepithelial vs luminal cellular compartment) (2–
9). Basal-like breast cancers arise from the basal/myoepithelial cell 
compartment, whereas non-basal-like cancers (ie, HER2-enriched, 
luminal B, and luminal A) emerge from a more luminal-like cell 
compartment.
Data in this commentary also suggest themes for future etiolog-
ical and clinical research. Large-scale and population-based epide-
miological studies could stratify etiological analyses by molecular 
subtypes such as basal-like vs non-basal-like or luminal. Our cur-
rent thinking is that there are two main etiological subtypes for 
sporadic breast cancers, but there could be a few more, potentially 
including rare subtypes such as inflammatory breast cancer (112). 
Given the challenges in molecular subtyping in large-scale pop-
ulation-based studies, it would be helpful to further develop and 
validate parsimonious robust marker panels for studies that merge 
individual-level molecular and clinical data in populations within 
well-defined catchment areas (173,182,183).
Figure  3. MEATBRIC case data for approximately 2000 breast tumors 
(179). Global gene expression was assessed with the intrinsic gene set. 
A) Density plots for age at diagnosis of basal-like cancers had an early-
onset mode near age 50 years. Luminal A and luminal B cases showed 
bimodal age distributions with predominant late-onset modes near age 
70  years and minor modes near age 50  years. The human epidermal 
growth factor receptor 2–enriched (HER2E) age distribution at diagnosis 
lies in between the density plots for the luminal and basal-like cancers. B) 
Combining HER2E and luminal cases into a single non-basal-like group 
did not appreciably alter the shape of the bimodal age distribution plots 
shown for molecular subtypes. C) Hazard rates of breast cancer–specific 
death for basal-like, HER2E, and luminal B cancers peaked near 7.5% 
per year approximately 2 years after initial breast cancer diagnosis then 
declined, similar to estrogen receptor (ER)–negative cases in the National 
Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) 
database (Figure 2C). Luminal A hazard rates lacked a sharp peak and 
were relatively constant at 2% to 2.5% per year, similar to ER-positive 
cases in SEER (Figure 2C). D) Combining the HER2E and luminal cases 
into a single non-basal-like group resulted in a hazard plot that was inter-
mediate between the basal-like and luminal A hazard rates. Hazard rates 
crossed over approximately 8 years after breast cancer diagnosis, similar 
to ER-positive and ER-negative cancers in SEER (Figure 2C).
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Understanding the etiological heterogeneity of breast cancer, 
whether it is fundamentally bimodal as proposed herein or more 
complex, would have critical implications for breast cancer preven-
tion. For example, selective ER modulators are effective in reduc-
ing breast cancer incidence among women at higher risk overall 
(184), but the means for identifying women specifically at elevated 
risk for hormonally driven cancers are lacking. Furthermore, 
ER-positive status is only a surrogate of hormone dependence; 
selective ER modulators do not prevent all ER-positive cancers nor 
do all ER-positive tumors respond to adjuvant endocrine therapy 
(4,185). If the hormone-responsive phenotype is linkable to a risk 
factor profile (eg, the etiological class of breast cancers enriched, 
but not exclusively within the late onset peak), then identifying this 
subtype more specifically would represent an advance with trans-
lational potential for both prevention and treatment. Similarly, 
understanding the basic biology of tumors enriched within the 
early-onset age distribution at diagnosis might offer analogous 
opportunities for BRCA1-related, basal-like, and/or triple-negative 
breast cancers.
As a final thought, although a two-component mixture model 
may seem too simplistic for breast cancer clinical heterogeneity, 
it is not too simple for etiology. Much of the clinical heterogene-
ity for breast cancer may result from tumor promotion and pro-
gression, which is very likely far downstream of tumor initiation 
(31). Therefore, breast cancer etiology (tumor initiation) may be 
less complex than subsequent tumor promotion and progression. 
Additionally, although parsimonious, the complexity of mixture 
models should not be underappreciated. The potential for an infi-
nite number of mixtures of just two main components is compli-
cated enough to account for much of the observed breast cancer 
heterogeneity.
references
 1. Henderson IC, Patek AJ. The relationship between prognostic and predic-
tive factors in the management of breast cancer. Breast Cancer Res Treat. 
1998;52(1–3):261–288.
 2. Anderson WF, Matsuno RK. Breast cancer heterogeneity: a mixture of at 
least two main types? J Natl Cancer Inst. 2006;98(14):948–951.
 3. Li JJ, Li SA, Mohla S, Rochefort H, Maudelonde T. Hormonal 
Carcinogenesis V. Advances in Experimental Medicine and Biology. Vol. 
617. New York: Springer; 2008. ISBN 978-0-387-69078-0.
 4. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast 
cancer response to aromatase inhibition. Nature. 2012;486(7403): 
353–360.
 5. Ithimakin S, Day KC, Malik F, et al. HER2 drives luminal breast cancer 
stem cells in the absence of HER2 amplification: implications for efficacy 
of adjuvant trastuzumab. Cancer Res. 2013;73(5):1635–1646.
 6. Korkaya H, Wicha MS. HER2 and breast cancer stem cells: more than 
meets the eye. Cancer Res. 2013;73(12):3489–3493.
 7. Korkaya H, Wicha MS. Breast cancer stem cells: we’ve got them sur-
rounded. Clin Cancer Res. 2013;19(3):511–513.
 8. Prat A, Perou CM. Mammary development meets cancer genomics. Nat 
Med. 2009;15(8):842–844.
 9. Prat A, Adamo B, Fan C, et al. Gene expression analyses across six can-
cer types identify basal-like breast cancer as a unique molecular entity. 
Scientific Rep. 2013;3:1–12.
 10. Armitage P, Doll R. A two-stage theory of carcinogenesis in relation to the 
age distribution of human cancer. Br J Cancer. 1957;11(2):161–169.
 11. Armitage P, Doll R. The age distribution of cancer and a multi-stage the-
ory of carcinogenesis. Br J Cancer. 1954;8(1):1–12.
 12. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 
2001;1(2):157–162.
 13. Doll R. Commentary: the age distribution of cancer and a multistage the-
ory of carcinogenesis. Int J Epidemiol. 2004;33(6):1183–1184.
 14. Frank SA. Commentary: mathematical models of cancer progression and 
epidemiology in the age of high throughput genomics. Int J Epidemiol. 
2004;33(6):1179–1181.
 15. Moolgavkar SH. Commentary: fifty years of the multistage model: remarks 
on a landmark paper. Int J Epidemiol. 2004;33(6):1182–1183.
Figure 4. Results and data herein suggest that breast cancer overall 
may be viewed as a hierarchal disease, consisting of a two-component 
mixture of two main cell types of origin (ie, luminal vs basal/myoepithe-
lial). As hypothesized in this cartoon, human epidermal growth factor 
receptor 2–enriched (HER2E) and luminal intrinsic molecular subtypes 
are initiated (lightning bolts) from the luminal cell compartment. On 
the other hand, in this model, basal-like breast cancers (HER2−/HR−) are 
initiated within the basal/myoepithelial cell compartment.
Vol. 106, Issue 8  |  dju165  |  August 13, 20148 of 11 Commentary | JNCI
 16. Clemmesen J. Carcinoma of the breast. Br J Radiol. 1948;21(252):583–590.
 17. Clemmesen J. On the etiology of some human cancers. J Natl Cancer Inst. 
1951;12(1):1–21.
 18. Muguti GI. Experience with breast cancer in Zimbabwe. J R Coll Surg 
Edinb. 1993;38(2):75–78.
 19. Chie WC, Chen CF, Lee WC, Chen CJ, Lin RS. Age-period-cohort analy-
sis of breast cancer mortality. Anticancer Res. 1995;15(2):511–515.
 20. Sant M, Gatta G, Micheli A, et  al. Survival and age at diagnosis of 
breast cancer in a population-based cancer registry. Eur J Cancer. 
1991;27(8):981–984.
 21. Thomas DB. Breast cancer in men. Epidemiol Rev. 1993;15(1):220–231.
 22. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG. 
“Hormonal” risk factors, “breast tissue age: and the age-incidence of breast 
cancer. Nature. 1983;303(5920):767–770.
 23. Pathak DR, Whittemore AS. Combined effects of body size, parity, and 
menstrual events on breast cancer incidence in seven countries. Am J 
Epidemiol. 1992;135(2):153–168.
 24. Rosner B, Colditz GA. Nurses’ Health Study: log-incidence mathematical 
model of breast cancer incidence. J Natl Cancer Inst. 1996;88(6):359–364.
 25. Rosner B, Colditz GA, Willett WC. Reproductive risk factors in a pro-
spective study of breast cancer: the Nurses’ Health Study. Am J Epidemiol. 
1994;139(8):819–835.
 26. Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcino-
genesis: epidemiology of breast cancer in females. J Natl Cancer Inst. 
1980;65(3):559–569.
 27. Lilienfeld AM, Johnson EA. The age distribution in female breast and 
genital cancers. Cancer. 1955;8:875–882.
 28. De Waard F. Premenopausal and postmenopausal breast cancer: one dis-
ease or two? J Natl Cancer Inst. 1979;63(3):549–552.
 29. De Waard F, Baanders-van Halewijn EA, Huizinga J. The bimodal age dis-
tribution of patients with mammary carcinoma; evidence for the existence 
of 2 types of human breast cancer. Cancer. 1964;17(2):141–151.
 30. De Waard F, De Laive JWJ, Baanders-van Halewijn EA. On bimodal age 
distribution of mammary carcinoma. Br J Cancer. 1960;14(3):437–448.
 31. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen recep-
tor breast cancer phenotypes in the Surveillance, Epidemiology, and End 
results database. Breast Cancer Res Treat. 2002;76(1):27–36.
 32. Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol 
Hematol. 2008;66(1):65–74.
 33. Yasui Y, Potter JD. The shape of age-incidence curves of female breast can-
cer by hormone- receptor status. Cancer Causes Control. 1999;10(5):431–437.
 34. Tarone RE, Chu KC. The greater impact of menopause on ER- than ER+ 
breast cancer incidence: a possible explanation (United States). Cancer 
Causes Control. 2002;13(1):7–14.
 35. Morabia A, Costanza MC. International variability in ages at menarche, 
first livebirth, and menopause. World Health Organization Collaborative 
Study of Neoplasia and Steroid Contraceptives. Am J Epidemiol. 
1998;148(12):1195–1205.
 36. Morabia A, Flandre P. Misclassification bias related to definition of men-
opausal status in case-control studies of breast cancer. Int J Epidemiol. 
1992;21(2):222–228.
 37. Anderson WF, Rosenberg PS, Menashe I, Mitani A, Pfeiffer RM. Age-
related crossover in breast cancer incidence rates between black and white 
ethnic groups. J Natl Cancer Inst. 2008;100(24):1804–1814.
 38. Anderson WF, Matsuno RK, Sherman ME, et al. Estimating age-specific 
breast cancer risks: a descriptive tool to identify age interactions. Cancer 
Causes Control. 2007;18(4):439–447.
 39. Anderson WF, Chen BE, Brinton LA, Devesa SS. Qualitative age interactions 
(or effect modification) suggest different cancer pathways for early-onset 
and late-onset breast cancers. Cancer Causes Control. 2007;18(10):1187–1198.
 40. Anderson WF, Jatoi I, Sherman ME. Qualitative age interactions in breast 
cancer studies: mind the gap. J Clin Oncol. 2009;27(32):5308–5311.
 41. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health 
Services. London: Nuffield Provincial Hospitals Trust; 1972.
 42. Peto R. Statistical Aspects of Cancer Trials. London: Chapman and Hall; 
1982.
 43. Anderson WF, Chu KC, Chatterjee N, Brawley OW, Brinton LA. 
Tumor variants by hormone receptor expression in white patients with 
node-negative breast cancer from the Surveillance, Epidemiology, and End 
Results database. J Clin Oncol. 2001;19(1):18–27.
 44. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and 
prognostic patterns in the NCI’s SEER program: suggesting a pos-
sible link between etiology and outcome. Breast Cancer Res Treat. 
2005;90(2):127–137.
 45. Anderson WF, Pfeiffer RM, Dores GM, Sherman ME. Comparison of age 
frequency distribution patterns for different histopathologic types of breast 
carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1899–1905.
 46. Desantis C, Howlader N, Cronin KA, Jemal A. Breast cancer incidence 
rates in US women are no longer declining. Cancer Epidemiol Biomarkers 
Prev. 2011;20(5):733–739.
 47. Anderson WF, Katki HA, Rosenberg PS. Breast cancer incidence 
in the United States: urrent and future trends. J Natl Cancer Inst. 
2011;103(18):1397–1402.
 48. Desantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA. 
Cancer J Clin. 2014;64(1):52–62.
 49. Berry DA, Ravdin PM. Breast cancer trends: a marriage between 
clinical trial evidence and epidemiology. J Natl Cancer Inst. 
2007;99(15):1139–1141.
 50. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical 
Oncology/College Of American Pathologists guideline recommendations 
for immunohistochemical testing of estrogen and progesterone receptors 
in breast cancer. J Clin Oncol. 2010;28(16):2784–2795.
 51. Porter PL, El-Bastawissi AY, Mandelson MT, et  al. Breast tumor 
characteristics as predictors of mammographic detection: com-
parison of interval- and screen-detected cancers. J Natl Cancer Inst. 
1999;91(23):2020–2028.
 52. Narod SA, Dube MP. Biologic characteristics of interval and screen-
detected breast cancers. J Natl Cancer Inst. 2001;93(2):151–152.
 53. Anderson WF, Rosenberg PS, Petito L, et al. Divergent estrogen receptor-
positive and -negative breast cancer trends and etiologic heterogeneity in 
Denmark. Int J Cancer. 2013;133(9):2201–2206.
 54. Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality 
in the United States: implications for prevention. Breast Cancer Res Treat. 
2013;138(3):665–673.
 55. Pfeiffer RM, Carroll RJ, Wheeler W, Whitby D, Mbulaiteye S. Combining 
assays for estimating prevalence of human herpesvirus 8 infection using 
multivariate mixture models. Biostatistics. 2008;9(1):137–151.
 56. Rosenberg PS, Anderson WF. Proportional hazard models and age-period-
cohort analysis of cancer rates. Stat Med. 2010;29(11):1228–1238.
 57. Holford TR. The estimation of age, period and cohort effects for vital 
rates. Biometrics. 983;39(2):311–324.
 58. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-spe-
cific incidence rate patterns for different histopathologic types of breast 
carcinoma. Cancer Epidemiol Biomarkers Prev. 2004;13(7):1128–1135.
 59. Marcus JN, Page DL, Watson P, Narod SA, Lenoir GM, Lynch HT. 
BRCA1 and BRCA2 hereditary breast carcinoma phenotypes. Cancer. 
1997;80(S3):543–556.
 60. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial 
breast cancer: histological features of cancers in families not attributable to 
mutations in BRCA1 or BRCA2. Clin Cancer Res. 2000;6(3):782–789.
 61. Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 
(Phila). 2002;34(4):309–314.
 62. Rosenberg PS, Anderson WF. Age-period-cohort models in cancer surveil-
lance research: ready for prime time? Cancer Epidemiol Biomarkers Prev. 
2011;20(7):1263–1268.
 63. Moolgavkar SH, Stevens RG, Lee JA. Effect of age on incidence of breast 
cancer in females. J Natl Cancer Inst. 1979;62(3):493–501.
 64. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The 
global picture. Eur J Cancer. 2001;37(Suppl 8):S4–66.
 65. MacMahon B. Breast cancer at menopausal ages: an explanation of 
observed incidence changes. Cancer. 1957;10(5):1037–1044.
 66. Lane-Claypon JE. A further report on cancer of the breast with special 
reference to its associated antecedent conditions. Rep Public Health Med 
Subj (Lond). 1926;32.
 67. MacMahon B, Cole P, Lin TM, et al. Age at first birth and breast cancer 
risk. Bull World Health Organ. 1970;43(2):209–221.
JNCI | Commentary 9 of 11jnci.oxfordjournals.org
 68. Cummings P, Weiss NS, McKnight B, Stanford JL. Estimating the risk 
of breast cancer in relation to the interval since last term pregnancy. 
Epidemiology. 1997;8(5):488–494.
 69. Thompson WD. Age at and time since: modeling temporal aspects of 
exposure. Epidemiology. 1997;8(5):471–473.
 70. Woods KL, Smith SR, Morrison JM. Parity and breast cancer: evidence of 
a dual effect. Br Med J. 1980;281(6237):419–421.
 71. Lubin JH, Burns PE, Blot WJ, et  al. Risk factors for breast cancer in 
women in northern Alberta, Canada, as related to age at diagnosis. J Natl 
Cancer Inst. 1982;68(2):211–217.
 72. Janerich DT, Hoff MB. Evidence for a crossover in breast cancer risk fac-
tors. Am J Epidemiol. 1982;116(5):737–742.
 73. Bruzzi P, Negri E, La Vecchia C, et al. Short term increase in risk of breast 
cancer after full term pregnancy. BMJ. 1988;297(6656):1096–1098.
 74. Williams EM, Jones L, Vessey MP, McPherson K. Short term increase 
in risk of breast cancer associated with full term pregnancy. BMJ. 
1990;300(6724):578–579.
 75. Hsieh C, Pavia M, Lambe M, et al. Dual effect of parity on breast cancer 
risk. Eur J Cancer. 1994;30A(7):969–973.
 76. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. 
Transient increase in the risk of breast cancer after giving birth. N Engl J 
Med. 1994;331(1):5–9.
 77. Leon DA, Carpenter LM, Broeders MJ, Gunnarskog J, Murphy MF. Breast 
cancer in Swedish women before age 50: evidence of a dual effect of com-
pleted pregnancy. Cancer Causes Control. 1995;6(4):283–291.
 78. Albrektsen G, Heuch I, Kvale G. The short-term and long-term effect of 
a pregnancy on breast cancer risk: a prospective study of 802,457 parous 
Norwegian women. Br J Cancer. 1995;72(2):480–484.
 79. Lambe M, Hsieh CC, Tsaih SW, Ekbom A, Trichopoulos D, Adami HO. 
Parity, age at first birth and the risk of carcinoma in situ of the breast. Int J 
Cancer. 1998;77(3):330–332.
 80. Wohlfahrt J, Olsen JH, Melby M. Breast cancer risk after childbirth in 
young women with family history (Denmark). Cancer Causes Control. 
2002;13(2):169–174.
 81. Pathak DR. Dual effect of first full term pregnancy on breast cancer 
risk: empirical evidence and postulated underlying biology. Cancer Causes 
Control. 2002;13(4):295–298.
 82. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of 
breast cancer. N Engl J Med. 1997;336(2):81v85.
 83. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat Rev 
Cancer. 2006;6(4):281–291.
 84. Lyons TR, Schedin PJ, Borges VF. Pregnancy and breast cancer: when they 
collide. J Mammary Gland Biol Neoplasia. 2009;14(2):87–98.
 85. Tiede B, Kang Y. From milk to malignancy: the role of mammary stem cells 
in development, pregnancy and breast cancer. Cell Res. 2011;21(2):245–257.
 86. Kobayashi S, Sugiura H, Ando Y, et  al. Reproductive history and breast 
cancer risk. Breast Cancer. 2012;19(4):302–308.
 87. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk 
factors for breast cancer according to estrogen and progesterone receptor 
status. J Natl Cancer Inst. 2004;96(3):218–228.
 88. Millikan RC, Newman B, Tse CK, et al. Epidemiology of basal-like breast 
cancer. Breast Cancer Res Treat. 2008;123(1):123–139.
 89. Shinde SS, Forman MR, Kuerer HM, et  al. Higher parity and shorter 
breastfeeding duration: association with triple-negative phenotype of 
breast cancer. Cancer. 2010;116(21):4933–4943.
 90. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer 
risk factors with tumor subtypes: a pooled analysis from the breast cancer 
association consortium studies. J Natl Cancer Inst. 2011;103(3):250–263.
 91. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral 
contraceptive use in relation to risk of triple-negative breast cancer. J Natl 
Cancer Inst. 2011;103(6):470–477.
 92. Clavel-Chapelon F, Gerber M. Reproductive factors and breast cancer 
risk. Do they differ according to age at diagnosis? Breast Cancer Res Treat. 
2002;72(2):107–115.
 93. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer 
and breastfeeding: collaborative reanalysis of individual data from 47 epide-
miological studies in 30 countries, including 50302 women with breast can-
cer and 96973 women without the disease. Lancet. 2002;360(9328):187–195.
 94. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast 
cancer risk according to joint estrogen and progesterone receptor status: a 
meta-analysis of epidemiological studies. Breast Cancer Res. 2006;8(4):R43.
 95. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and 
hormonal risk factors for postmenopausal luminal, HER-2-overexpressing, 
and triple-negative breast cancer. Cancer. 2008;113(7):1521–1526.
 96. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes 
of breast cancer across a population-based study of women 56  years or 
younger. Breast Cancer Res Treat. 2011;130(2):587–597.
 97. Kotsopoulos J, Lubinski J, Salmena L, et al. Breastfeeding and the risk of 
breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 
2012;14(2):R42.
 98. Li CI, Beaber EF, Tang MT, Porter PL, Daling JR, Malone KE. 
Reproductive factors and risk of estrogen receptor positive, triple-negative, 
and HER2-neu overexpressing breast cancer among women 20–44 years of 
age. Breast Cancer Res Treat. 2013;137(2):579–587.
 99. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and 
risk of luminal, HER2-overexpressing, and triple-negative breast can-
cer in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 
2008;17(8):2078–2086.
 100. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of 
developing premenopausal versus postmenopausal breast cancer. Proc Soc 
Exp Biol Med. 1997;216(1):28–43.
 101. Wu Q, Ishikawa T, Sirianni R, et  al. 27-Hydroxycholesterol pro-
motes cell-autonomous, er-positive breast cancer growth. Cell Rep. 
2013;5(3):637–645.
 102. Nelson ER, Wardell SE, Jasper JS, et  al. 27-Hydroxycholesterol links 
hypercholesterolemia and breast cancer pathophysiology. Science. 
2013;342(6162):1094–1098.
 103. Warner M, Gustafsson JA. On estrogen, cholesterol metabolism, and 
breast cancer. N Engl J Med. 2014;370(6):572–573.
 104. Huang Z, Hankinson SE, Colditz GA, et  al. Dual effects of weight and 
weight gain on breast cancer risk. JAMA. 1997;278(17):1407–1411.
 105. Lahmann PH, Hoffmann K, Allen N, et al. Body size and breast cancer 
risk: findings from the European Prospective Investigation into Cancer 
And Nutrition (EPIC). Int J Cancer. 2004;111(5):762–771.
 106. Carmichael AR, Bates T. Obesity and breast cancer: a review of the litera-
ture. Breast (Edinburgh, Scotland). 2004;13(2):85–92.
 107. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of 
weight before and after menopause with risk of postmenopausal breast 
cancer in the Iowa women’s health study. Cancer Epidemiol Biomarkers Prev. 
2005;14(3):656–661.
 108. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. 
Adult weight change and risk of postmenopausal breast cancer. JAMA. 
2006;296(2):193–201.
 109. Teras LR, Goodman M, Patel AV, Diver WR, Flanders WD, Feigelson 
HS. Weight loss and postmenopausal breast cancer in a prospec-
tive cohort of overweight and obese US women. Cancer Causes Control. 
2011;22(4):573–579.
 110. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan 
MP, Sherman ME. Etiology of hormone receptor-defined breast cancer: 
a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 
2004;13(10):1558–1568.
 111. Chang S, Buzdar AU, Hursting SD. Inflammatory breast cancer and body 
mass index. J Clin Oncol. 1998;16(12):3731–3735.
 112. Schairer C, Li Y, Frawley P, et  al. Risk factors for inflammatory 
breast cancer and other invasive breast cancer. J Natl Cancer Inst. 
2013;105(18):1373–1384.
 113. Tarone RE. Breast cancer trends among young women in the United 
States. Epidemiology. 2006;17(5):588–590.
 114. Lidegarrd O, Kroman N. The epidemiology of breast cancer. Eur Clinics 
Obstet Gynaecol. 2005;1(1):24–28.
 115. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions 
according to the Human Development Index (2008–2030): a population-
based study. Lancet Oncol. 2012;13(8):790–801.
 116. Karp SE, Tonin PN, Begin LR, et  al. Influence of BRCA1 mutations 
on nuclear grade and estrogen receptor status of breast carcinoma in 
Ashkenazi Jewish women. Cancer. 1997;80(3):435–441.
Vol. 106, Issue 8  |  dju165  |  August 13, 201410 of 11 Commentary | JNCI
 117. Loman N, Johannsson O, Bendahl PO, Borg A, Ferno M, Olsson H. Steroid 
receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 
mutations or unknown susceptibility genes. Cancer. 1998;83(2):310–319.
 118. Foulkes WD, Metcalfe K, Sun P, et al. Estrogen receptor status in BRCA1- 
and BRCA2-related breast cancer: the influence of age, grade, and histo-
logical type. Clin Cancer Res. 2004;10(6):2029–2034.
 119. Michailidou K, Hall P, Gonzalez-Neira A, et  al. Large-scale genotyp-
ing identifies 41 new loci associated with breast cancer risk. Nat Genet. 
2013;45(4):353–361.
 120. Garcia-Closas M, Hall P, Nevanlinna H, et  al. Heterogeneity of breast 
cancer associations with five susceptibility loci by clinical and pathological 
characteristics. PLoS Genet. 2008;4(4):e1000054.
 121. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer 
by estrogen receptor status. Clin Cancer Res. 2008;14(24):8000–8009.
 122. Li J, Humphreys K, Darabi H, et al. A genome-wide association scan on 
estrogen receptor-negative breast cancer. Breast Cancer Res. 2010;12(6):R93.
 123. Figueroa JD, Garcia-Closas M, Humphreys M, et al. Associations of com-
mon variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk 
and heterogeneity by tumor subtype: findings from the Breast Cancer 
Association Consortium. Hum Mol Genet. 2011;20(23):4693–4706.
 124. Broeks A, Schmidt MK, Sherman ME, et al. Low penetrance breast can-
cer susceptibility loci are associated with specific breast tumor subtypes: 
findings from the Breast Cancer Association Consortium. Hum Mol Genet. 
2011;20(16):3289–3303.
 125. Haiman CA, Chen GK, Vachon CM, et  al. A common variant at the 
TERT-CLPTM1L locus is associated with estrogen receptor-negative 
breast cancer. Nat Genet. 2011;43(12):1210–1214.
 126. Hein R, Maranian M, Hopper JL, et al. Comparison of 6q25 breast cancer 
hits from Asian and European genome wide association studies in the Breast 
Cancer Association Consortium (BCAC). PLoS One. 2012;7(8):e42380.
 127. Lambrechts D, Truong T, Justenhoven C, et  al. 11q13 is a suscepti-
bility locus for hormone receptor positive breast cancer. Hum Mutat. 
2012;33(7):1123–1132.
 128. Stevens KN, Fredericksen Z, Vachon CM, et  al. 19p13.1 is a tri-
ple-negative-specific breast cancer susceptibility locus. Cancer Res. 
2012;72(7):1795–1803.
 129. Garcia-Closas M, Couch FJ, Lindstrom S, et al. Genome-wide association 
studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 
2013;45(4):392–398.
 130. Bojesen SE, Pooley KA, Johnatty SE, et al. Multiple independent variants 
at the TERT locus are associated with telomere length and risks of breast 
and ovarian cancer. Nat Genet. 2013;45(4):371–384.
 131. Stevens KN, Vachon CM, Couch FJ. Genetic susceptibility to triple-nega-
tive breast cancer. Cancer Res. 2013;73(7):2025–2030.
 132. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classifi-
cation, prognostication, and prediction. Lancet. 2011;378(9805):1812–1823.
 133. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast 
tumours. Nature. 2000;406(6797):747–752.
 134. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast 
carcinomas distinguish tumor subclasses with clinical implications. Proc 
Natl Acad Sci U S A. 2001;98(19):10869–10874.
 135. Chung CH, Bernard PS, Perou CM. Molecular portraits and the family 
tree of cancer. Nat Genet. 2002;32(Suppl):533–540.
 136. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor 
subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 
2003;100(14):8418–8423.
 137. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression 
profiles in breast cancer: toward a unified understanding of breast cancer 
subtyping and prognosis signatures. Breast Cancer Res. 2008;10(4):R65.
 138. The Cancer Genome Atlas Network. Comprehensive molecular portraits 
of human breast tumours. Nature. 2012;490(7418):61–70.
 139. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like sub-
type of breast ductal carcinoma in situ. Hum Pathol. 2007;38(2):197–204.
 140. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-
like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264–271.
 141. Tamimi RM, Baer HJ, Marotti J, et al. Comparison of molecular pheno-
types of ductal carcinoma in situ and invasive breast cancer. Breast Cancer 
Res. 2008;10(4):R67.
 142. Yu K, Lee CH, Tan PH, Tan P. Conservation of breast cancer molecular 
subtypes and transcriptional patterns of tumor progression across distinct 
ethnic populations. Clin Cancer Res. 2004;10(16):5508–5517.
 143. Calza S, Hall P, Auer G, et  al. Intrinsic molecular signature of breast 
cancer in a population-based cohort of 412 patients. Breast Cancer Res. 
2006;8(4):R34.
 144. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer 
subtypes in premenopausal and postmenopausal African-American women: 
age-specific prevalence and survival. J Surg Res. 2007;143(1):109–118.
 145. Winer EP, Carey LA, Dowsett M, Tripathy D. Beyond anatomic staging: 
are we ready to take the leap to molecular classification? In: Perry MC, 
ed. American Society of Clinical Onocolgy Education Book. Alexandria, VA: 
American Society of Clinical Oncology; 2005:46–59.
 146. Fan C, Oh DS, Wessels L, et  al. Concordance among gene-expression-
based predictors for breast cancer. N Engl J Med. 2006;355(6):560–569.
 147. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast 
cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–1167.
 148. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adju-
vant therapy: time to consider its time-dependent effects. J Clin Oncol. 
2011;29(17):2301–2304.
 149. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and sur-
vival in the Carolina Breast Cancer Study. JAMA. 2006;295(21):2492–2502.
 150. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic 
significance of the basal-like subtype of breast cancer: a comparison with 
hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol. 
2006;37(9):1217–1226.
 151. Carey LA, Dees EC, Sawyer L, et  al. The triple negative paradox: pri-
mary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 
2007;13(8):2329–2334.
 152. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular sub-
types respond differently to preoperative chemotherapy. Clin Cancer Res. 
2005;11(16):5678–5685.
 153. Wo JY, Taghian AG, Nguyen PL, et al. The association between biological 
subtype and isolated regional nodal failure after breast-conserving therapy. 
Int J Radiat Oncol Biol Phys. 2010;77(1):188–196.
 154. Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-
based assays for breast oncologists. Nat Rev Clin Oncol. 2012;9(1):48–57.
 155. Haque R, Ahmed SA, Inzhakova G, et  al. Impact of breast cancer sub-
types and treatment on survival: an analysis spanning two decades. Cancer 
Epidemiol Biomarkers Prev. 2012;21(10):1848–1855.
 156. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a thera-
peutic roadmap. Cancer Disc. 2013;3(1):27–34.
 157. Goldhirsch A, Wood WC, Coates AS, et  al. Strategies for subtypes—
dealing with the diversity of breast cancer: highlights of the St. Gallen 
International Expert Consensus on the Primary Therapy of Early Breast 
Cancer 2011. Ann Oncol. 2011;22(8):1736–1747.
 158. Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. 
Molecular characterization of basal-like and non-basal-like triple-negative 
breast cancer. Oncologist. 2013;18(2):123–133.
 159. Prat A, Cheang MC, Martin M, et al. Prognostic significance of progester-
one receptor-positive tumor cells within immunohistochemically defined 
luminal a breast cancer. J Clin Oncol. 2013;31(2):203–209.
 160. Cancer Genome Atlas Network. Comprehensive molecular portraits of 
human breast tumours. Nature. 2012;490(7418):61–70.
 161. Ciriello G, Sinha R, Hoadley KA, et al. The molecular diversity of luminal 
A breast tumors. Breast Cancer Res Treat. 2013;141(3):409–420.
 162. Sorlie T, Wang Y, Xiao C, et al. Distinct molecular mechanisms underly-
ing clinically relevant subtypes of breast cancer: gene expression analyses 
across three different platforms. BMC Genomics. 2006;7(1):127.
 163. Sorlie T. Introducing molecular subtyping of breast cancer into the clinic? 
J Clin Oncol. 2009;27(8):1153–1154.
 164. Gierach GL, Burke A, Anderson WF. Epidemiology of triple negative 
breast cancers. Breast Dis. 2010;32(1–2):5–24.
 165. Perou CM. Molecular stratification of triple-negative breast cancers. 
Oncologist. 2010;15(Suppl 5):39–48.
 166. Lusa L, McShane LM, Reid JF, et  al. Challenges in projecting cluster-
ing results across gene expression-profiling datasets. J Natl Cancer Inst. 
2007;99(22):1715–1723.
JNCI | Commentary 11 of 11jnci.oxfordjournals.org
 167. Weigelt B, Mackay A, A’Hern R, et al. Breast cancer molecular profiling 
with single sample predictors: a retrospective analysis. Lancet Oncol. Apr 
2010;11(4):339–349.
 168. Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementa-
tion of the intrinsic subtypes of breast cancer. Lancet Oncol. 2010;11(8):718–
719; author reply 720–721.
 169. Sorlie T, Borgan E, Myhre S, et  al. The importance of gene-centring 
microarray data. Lancet Oncol. 2010;11(8):719–720; author reply 720–721.
 170. Hoadley KA, Yau C, Wolf DM, et al. Multi-platform integration of 12 
cancer types reveals cell-of-origin with distinct molecular signatures. Cell. 
2014; in press.
 171. Ghabach B, Anderson WF, Curtis RE, Huycke MM, Lavigne JA, Dores 
GM. Adenoid cystic carcinoma of the breast in the United States (1977–
2006): a population-based cohort study. Breast Cancer Res. 2012;12(4):R54.
 172. Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene 
model for identifying the major and clinically relevant molecular subtypes 
of breast cancer. Breast Cancer Res Treat. 2012;135(1):301–306.
 173. Anderson WF, Luo S, Chatterjee N, et  al. Human epidermal growth 
factor receptor-2 and estrogen receptor expression, a demonstra-
tion project using the residual tissue respository of the Surveillance, 
Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 
2009;113(1):189–196.
 174. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer 
subtypes: a study from the California Cancer Registry. Breast Cancer Res 
Treat. 2011;127(2):471–478.
 175. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast 
cancer subtypes among women in four racial/ethnic groups. Breast Cancer 
Res. 2010;12(6):R99.
 176. Keegan TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence 
of breast cancer subtypes in adolescent and young adult women. Breast 
Cancer Res. 2012;14(2):R55.
 177. Clarke CA, Keegan TH, Yang J, et al. Age-specific incidence of breast can-
cer subtypes: understanding the black-white crossover. J Natl Cancer Inst. 
2012;104(14):1094–1101.
 178. SEER-18. Surveillance, Epidemiology, and End Results (SEER) program 
(www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs 
Custom Data (includes additional CS SSF data for 2010 cases), Nov 2012 
Sub (2000–2010) <Katrina/Rita Population Adjustment> - Linked To County 
Attributes - Total U.S., 1969–2011 Counties, National Cancer Institute, 
DCCPS, Surveillance Research Program, Surveillance Systems Branch, 
released May 2013, based on November 2012 submission. 2012. www.seer.
cancer.gov. Accessed May 1, 2014. 
 179. Curtis C, Shah SP, Chin SF, et  al. The genomic and transcriptomic 
architecture of 2,000 breast tumours reveals novel subgroups. Nature. 
2012;486(7403):346–352.
 180. Dawson SJ, Rueda OM, Aparicio S, Caldas C. A new genome-driven 
integrated classification of breast cancer and its implications. EMBO J. 
2013;32(5):617–628.
 181. Boecker W, Buerger H. Evidence of progenitor cells of glandular and 
myoepithelial cell lineages in the human adult female breast epithelium: 
a new progenitor (adult stem) cell concept. Cell Prolif. 2003;36(Suppl 
1):73–84.
 182. Goodman MT, Hernandez BY, Hewitt S, et al. Tissues from population-
based cancer registries: a novel approach to increasing research potential. 
Hum Pathol. Jul 2005;36(7):812–820.
 183. Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human papillomavirus and 
rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 
2011;29(32):4294–4301.
 184. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of 
breast cancer: report of the National Surgical Adjuvant Breast And Bowel 
Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–1388.
 185. Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress 
and therapeutic implications. J Clin Oncol. 2005;23(8):1616–1622.
 186. Anderson WF, Reiner AS, Matsuno RK, Pfeiffer RM. Shifting breast can-
cer trends in the United States. J Clin Oncol. 2007;25(25):3923–3929.
 187. Rosenberg PS. Hazard function estimation using B-splines. Biometrics. 
1995;51(3):874–887.
 188. Akaike H. Information theory and an extension of the maximum likeli-
hood principle. Paper presented at 2nd International Symposium on 
Information Theory; 1973; Budapest, Hungary.
 189. Efron B, Tibshirani R. An Introduction to the Bootstrap. Monographs on 
Statistics and Applied Probability 57. New York: Chapman & Hall; 1993.
Funding
This research was supported in part by the Intramural Research Program of the 
National Institutes of Health (NIH), National Cancer Institute (NCI), and by 
extramural funds to CMP (NCI Breast SPORE program; P50-CA58223-09A1).
notes
The authors had full access to all of the data in the study and take responsibil-
ity for the integrity of the data and the accuracy of reported findings. CMP is 
an equity stock holder and board of director member of BioClassifier LLC and 
University Genomics. CMP is also listed an inventor on a patent application on 
the PAM50 molecular assay.
We wish to thank Dr Hyuna Sung and Mr David Check, Department of 
Health and Human Services/NIH/NCI/Division of Cancer Epidemiology and 
Genetics for advice and enhancements for Figure 4.
Affiliations of authors: Division of Cancer Epidemiology and Genetics 
Biostatistics Branch (WFA, PSR), and Division of Cancer Prevention 
(MES), National Cancer Institute, National Institutes of Health, Bethesda, 
MD; Translational Genomics Group, Vall d´Hebron Institute of Oncology, 
Barcelona, Spain (AP); Department of Genetics and Pathology & Laboratory 
Medicine, Lineberger Comprehensive Cancer Center, University of North 
Carolina at Chapel Hill, Chapel Hill, NC (CMP).
